Indian clinical trials along
with the overall healthcare vertical today are at an inflection point
and are estimated to expand in the long run. However, the Indian
clinical expenditure ranks still one of the lowest globally and there
are other critical challenges too that needs to be addressed in terms
of quality patient care and availability of health care services.
Though this represents a crucial scope for the private sector
the Government sector too has an essential part to play it making the
evolution possible.
The
health care and the clinical trial expenditure when compared with
regards to the public-private contribution, also indicates a
distorted picture. It has been estimated that the private sector
contribution to the India medical sector had been 75 percent and is
considered as the highest globally in terms of percentage. The public
expenditure on the other hand is estimated to be the lowest globally
and is also 23 percent less than the global average.
However,
apart from these statistical details changes in lifestyle and the
emergence of new chronic ailments have given rise to the amount of
clinical trials in India. This branches out from the intricacy of the
non-communicable and communicable diseases both in the urban and
rural regions. The occurrence of chronic disease patterns has
influenced the medical infrastructure needs and has also resulted in
the architectural challenges for the government as well as the
private players. It has also been observed that India often gets
rated poorly on the fundamental health care factors when it is
benchmarked against developed economies as well as the BRIC nations.
This indicates that a huge part of the Indian population is not able
to have proper access to health care services. This is a result of:
- Absence of proper medical infrastructure
- Absence of qualified and trained manpower
- Absence of proper regulatory services and quality assurance
Keeping
these aspects in mind Indian CRO’s (clinical research
organizations) today conducts regular clinical trials concentrating
on Phase I to IV medical studies. These CRO’s apart from carrying
out innovative drug development
and treatment process also carries out research on innovative medical
studies on biometrics,
medical writing, clinical pharmacokinetic, and
other variations of bio-analytical studies. In additional to that,
the CRO’s also excel in multiple therapeutic areas and studies
related to bioavailability.
Thus,
the major objective of having systematic and organized clinical trial
phases is to come out with innovative treatment methods and healing
modalities so that the rate of chronic ailments can be reduced
eventually.
Read
mor on - biometrics
companies
No comments:
Post a Comment